1	The	The	B-NP	DT	O	2	NMOD	-1
2	merits	merit	I-NP	NNS	O	0	ROOT	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	vascular	vascular	B-NP	JJ	O	5	NMOD	-1
5	targeting	targeting	I-NP	NN	O	3	PMOD	0
6	for	for	B-PP	IN	O	5	NMOD	-1
7	gynecologic	gynecologic	B-NP	JJ	O	8	NMOD	-1
8	malignancies	malignancy	I-NP	NNS	O	6	PMOD	-1
9	.	.	O	.	O	2	P	-1

1	Neovascularization	Neovascularization	B-NP	NN	O	2	SUB	3	Neovascularization
2	is	be	B-VP	VBZ	O	0	ROOT	-1
3	an	an	B-NP	DT	O	7	NMOD	-1
4	early	early	I-NP	JJ	O	7	NMOD	-1
5	and	and	I-NP	CC	O	7	NMOD	-1
6	critical	critical	I-NP	JJ	O	7	NMOD	0
7	step	step	I-NP	NN	O	2	PRD	-1
8	in	in	B-PP	IN	O	7	NMOD	-1
9	tumor	tumor	B-NP	NN	O	10	NMOD	-1
10	development	development	I-NP	NN	O	12	NMOD	2	development
11	and	and	O	CC	O	12	NMOD	-1
12	progression	progression	B-NP	NN	O	8	PMOD	2	progression
13	.	.	O	.	O	2	P	-1

1	Tumor	Tumor	B-NP	NN	O	2	NMOD	-1
2	vessels	vessel	I-NP	NNS	O	3	SUB	-1
3	are	be	B-VP	VBP	O	0	ROOT	-1
4	distinct	distinct	B-ADJP	JJ	O	3	PRD	-1
5	from	from	B-PP	IN	O	4	AMOD	-1
6	their	their	B-NP	PRP$	O	8	NMOD	-1
7	normal	normal	I-NP	JJ	O	8	NMOD	-1
8	counterparts	counterpart	I-NP	NNS	O	5	PMOD	-1
9	morphologically	morphologically	O	RB	O	3	VMOD	-1
10	as	as	B-CONJP	RB	O	9	DEP	-1
11	well	well	I-CONJP	RB	O	10	DEP	-1
12	as	as	I-CONJP	IN	O	10	DEP	-1
13	at	at	B-PP	IN	O	9	PMOD	-1
14	a	a	B-NP	DT	O	16	NMOD	-1
15	molecular	molecular	I-NP	JJ	O	16	NMOD	-1
16	level	level	I-NP	NN	O	13	PMOD	-1
17	.	.	O	.	O	3	P	-1

1	Recent	Recent	B-NP	JJ	O	2	NMOD	-1
2	studies	study	I-NP	NNS	O	10	SUB	-1
3	on	on	B-PP	IN	O	2	NMOD	-1
4	factors	factor	B-NP	NNS	O	3	PMOD	-1
5	involved	involve	B-VP	VBN	O	4	NMOD	0
6	in	in	B-PP	IN	O	5	VMOD	-1
7	tumor	tumor	B-NP	NN	O	9	NMOD	-1
8	vascular	vascular	I-NP	JJ	O	9	NMOD	-1
9	development	development	I-NP	NN	O	6	PMOD	2	development
10	have	have	B-VP	VBP	O	0	ROOT	-1
11	identified	identify	I-VP	VBN	O	10	VC	-1
12	new	new	B-NP	JJ	O	14	NMOD	-1
13	therapeutic	therapeutic	I-NP	JJ	O	14	NMOD	-1
14	targets	target	I-NP	NNS	O	11	OBJ	0
15	for	for	B-PP	IN	O	11	VMOD	-1
16	inhibiting	inhibit	B-VP	VBG	O	15	PMOD	18	inhibiting
17	tumor	tumor	B-NP	NN	O	18	NMOD	-1
18	neovascularization	neovascularization	I-NP	NN	O	22	NMOD	3	neovascularization
19	and	and	O	CC	O	22	NMOD	-1
20	thus	thus	B-ADVP	RB	O	22	NMOD	-1
21	tumor	tumor	B-NP	NN	O	22	NMOD	-1
22	progression	progression	I-NP	NN	O	16	OBJ	2	progression
23	.	.	O	.	O	10	P	-1

1	However	However	B-ADVP	RB	O	16	VMOD	-1
2	,	,	O	,	O	16	P	-1
3	the	the	B-NP	DT	O	4	NMOD	-1
4	process	process	I-NP	NN	O	10	SUB	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	tumor	tumor	B-NP	NN	O	9	NMOD	-1
7	blood	blood	I-NP	NN	O	9	NMOD	-1
8	vessel	vessel	I-NP	NN	O	9	NMOD	-1
9	formation	formation	I-NP	NN	O	5	PMOD	2	formation
10	is	be	B-VP	VBZ	O	16	VMOD	-1
11	complex	complex	B-ADJP	JJ	O	10	PRD	-1
12	,	,	O	,	O	16	P	-1
13	and	and	O	CC	O	16	VMOD	-1
14	each	each	B-NP	DT	O	15	NMOD	-1
15	tumor	tumor	I-NP	NN	O	16	SUB	-1
16	exhibits	exhibit	B-VP	VBZ	O	0	ROOT	-1
17	unique	unique	B-NP	JJ	O	18	NMOD	-1
18	features	feature	I-NP	NNS	O	16	OBJ	-1
19	in	in	B-PP	IN	O	16	VMOD	-1
20	its	its	B-NP	PRP$	O	21	NMOD	-1
21	vasculature	vasculature	I-NP	NN	O	19	PMOD	-1
22	.	.	O	.	O	16	P	-1

1	An	An	B-NP	DT	O	2	NMOD	-1
2	understanding	understanding	I-NP	NN	O	16	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	the	the	B-NP	DT	O	6	NMOD	-1
5	relative	relative	I-NP	JJ	O	6	NMOD	-1
6	contribution	contribution	I-NP	NN	O	3	PMOD	0
7	of	of	B-PP	IN	O	6	NMOD	-1
8	various	various	B-NP	JJ	O	9	NMOD	-1
9	pathways	pathway	I-NP	NNS	O	7	PMOD	0
10	in	in	B-PP	IN	O	6	NMOD	-1
11	the	the	B-NP	DT	O	12	NMOD	-1
12	development	development	I-NP	NN	O	10	PMOD	2	development
13	of	of	B-PP	IN	O	12	NMOD	-1
14	tumor	tumor	B-NP	NN	O	15	NMOD	-1
15	vasculature	vasculature	I-NP	NN	O	13	PMOD	-1
16	is	be	B-VP	VBZ	O	0	ROOT	-1
17	critical	critical	B-ADJP	JJ	O	16	PRD	0
18	for	for	B-PP	IN	O	17	AMOD	-1
19	developing	develop	B-VP	VBG	O	18	PMOD	0
20	effective	effective	B-NP	JJ	O	22	AMOD	0
21	and	and	I-NP	CC	O	22	AMOD	-1
22	selective	selective	I-NP	JJ	O	24	NMOD	-1
23	therapeutic	therapeutic	I-NP	JJ	O	24	NMOD	-1
24	approaches	approach	I-NP	NNS	O	19	OBJ	-1
25	.	.	O	.	O	16	P	-1

1	Several	Several	B-NP	JJ	O	3	NMOD	-1
2	such	such	I-NP	JJ	O	3	NMOD	-1
3	agents	agent	I-NP	NNS	O	4	SUB	-1
4	are	be	B-VP	VBP	O	13	VMOD	-1
5	currently	currently	B-ADVP	RB	O	4	VMOD	-1
6	in	in	B-PP	IN	O	4	VMOD	-1
7	clinical	clinical	B-NP	JJ	O	8	NMOD	-1
8	trials	trial	I-NP	NNS	O	6	PMOD	-1
9	,	,	O	,	O	13	P	-1
10	and	and	O	CC	O	13	VMOD	-1
11	many	many	B-NP	JJ	O	12	NMOD	-1
12	others	other	I-NP	NNS	O	13	SUB	-1
13	are	be	B-VP	VBP	O	0	ROOT	-1
14	under	under	B-PP	IN	O	13	PRD	-1
15	development	development	B-NP	NN	O	14	PMOD	0
16	.	.	O	.	O	13	P	-1

1	In	In	B-PP	IN	O	15	VMOD	-1
2	this	this	B-NP	DT	O	3	NMOD	-1
3	review	review	I-NP	NN	O	1	PMOD	-1
4	,	,	O	,	O	15	P	-1
5	the	the	B-NP	DT	O	8	NMOD	-1
6	mechanisms	mechanism	I-NP	NNS	O	8	NMOD	-1
7	and	and	I-NP	CC	O	8	NMOD	-1
8	factors	factor	I-NP	NNS	O	15	SUB	-1
9	involved	involve	B-VP	VBN	O	8	NMOD	0
10	in	in	B-PP	IN	O	9	VMOD	-1
11	tumor	tumor	B-NP	NN	O	14	NMOD	-1
12	blood	blood	I-NP	NN	O	14	NMOD	-1
13	vessel	vessel	I-NP	NN	O	14	NMOD	-1
14	formation	formation	I-NP	NN	O	10	PMOD	2	formation
15	are	be	B-VP	VBP	O	0	ROOT	-1
16	discussed	discuss	I-VP	VBN	O	15	VC	-1
17	.	.	O	.	O	15	P	-1

1	In	In	B-PP	IN	O	25	VMOD	-1
2	addition	addition	B-NP	NN	O	1	PMOD	0
3	,	,	O	,	O	25	P	-1
4	selected	select	B-NP	VBN	O	6	NMOD	-1
5	novel	novel	I-NP	JJ	O	6	NMOD	-1
6	classes	class	I-NP	NNS	O	25	SUB	-1
7	of	of	B-PP	IN	O	6	NMOD	-1
8	antivascular	antivascular	B-NP	JJ	O	9	NMOD	-1
9	therapies	therapy	I-NP	NNS	O	7	PMOD	0
10	,	,	O	,	O	9	P	-1
11	including	include	B-PP	VBG	O	9	NMOD	-1
12	those	those	B-NP	DT	O	16	NMOD	-1
13	targeting	target	I-NP	VBG	O	16	NMOD	19	targeting
14	tumor	tumor	I-NP	NN	B-cell_type	16	NMOD	-1
15	endothelial	endothelial	I-NP	JJ	I-cell_type	16	NMOD	-1
16	cells	cell	I-NP	NNS	I-cell_type	19	NMOD	-1
17	and	and	O	CC	O	19	NMOD	-1
18	other	other	B-NP	JJ	O	19	NMOD	-1
19	components	component	I-NP	NNS	O	11	PMOD	-1
20	of	of	B-PP	IN	O	19	NMOD	-1
21	the	the	B-NP	DT	O	23	NMOD	-1
22	tumor	tumor	I-NP	NN	O	23	NMOD	-1
23	vasculature	vasculature	I-NP	NN	O	20	PMOD	-1
24	,	,	O	,	O	6	P	-1
25	are	be	B-VP	VBP	O	0	ROOT	-1
26	summarized	summarize	I-VP	VBN	O	25	VC	-1
27	.	.	O	.	O	25	P	-1

